Analyst consensus shifted notably on August 1, with target price upgrades dominating the pharma space while construction materials drew cuts.
REGN received a target lift to $833.54. That is up from $830.02. Regeneron carries a $73.8bn market cap and short interest sits at just 3.5% of free float — suggesting bears are not positioned against the bullish analyst tide.
BIIB also got a target boost, with the consensus moving to $234.35. Both Regeneron and Biogen benefit from strong drug pipelines drawing renewed Wall Street interest.
On the downside, MLM — Martin Marietta Materials — saw its average target trimmed to $671.61 from $676.48. The $32.4bn aggregates group is feeling analyst caution. Infrastructure spending optimism has cooled slightly.
CTVA presented a split picture. One analyst cut the target while another raised it. The net consensus settled at $91.70. The agrochemical giant has a $59.8bn cap and very low short interest at 2.7% of free float.
WST — West Pharmaceutical Services — got a target upgrade to $404.73. The pharmaceutical packaging company has a $23.9bn market cap. Analysts see upside despite a broadly cautious healthcare environment.
The clearest theme: pharma targets are moving up. Materials and chemicals face headwinds. Watch Martin Marietta for further analyst pressure if infrastructure data disappoints.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
